<?xml version='1.0' encoding='UTF-8'?><?xml-stylesheet type='text/xsl' href='http://rss.feedsportal.com/xsl/nl/rss.xsl'?>
<rss xmlns:itunes="http://www.itunes.com/dtds/podcast-1.0.dtd" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:taxo="http://purl.org/rss/1.0/modules/taxonomy/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" version="2.0"><channel><title>Analist.be - Alle adviezen</title><link>http://www.analist.be</link><description>De laatste koop- en verkoopadviezen</description><language>nl-nl</language><copyright>Copyright 2006-2012 Analist.be</copyright><pubDate>Tue, 07 Feb 2012 09:18:52 GMT</pubDate><lastBuildDate>Tue, 07 Feb 2012 09:18:52 GMT</lastBuildDate><ttl>2</ttl><image><title>Analist.be - Alle adviezen</title><url>http://www.analist.be/images/analist_logo_be2.gif</url><link>http://www.analist.be</link></image><item><title>Barclays: Sirius XM Radio verkopen.</title><link>http://rss.feedsportal.com/c/634/f/8249/s/1c74b57c/l/0L0Sanalist0Bbe0Crss0Ibe0Bphp0Did0F120A421/story01.htm</link><description>Glasgow - Op 7-2-2012 (her)starten de analisten van Barclays met het volgen van de Amerikaanse mediabedrijf Sirius XM Radio (ISIN: US82966U1034) met een verkoopadvies. nnHet 12-maands koersdoel voor het aandeel Sirius XM Radio is vastgesteld op 2.00 USD. In 2010 bedroeg de.. (lees verder op: www.analist.be)&lt;img width='1' height='1' src='http://rss.feedsportal.com/c/634/f/8249/s/1c74b57c/mf.gif' border='0'/&gt;&lt;div class='mf-viral'&gt;&lt;table border='0'&gt;&lt;tr&gt;&lt;td valign='middle'&gt;&lt;a href="http://res.feedsportal.com/viral/sendEmail.cfm?lang=nl&amp;title=Barclays%3A+Sirius+XM+Radio+verkopen.&amp;link=http%3A%2F%2Fwww.analist.be%2Frss_be.php%3Fid%3D120421" target="_blank"&gt;&lt;img src="http://res3.feedsportal.com/images/emailthis2_nl.gif" border="0" /&gt;&lt;/a&gt;&lt;/td&gt;&lt;td valign='middle'&gt;&lt;a href="http://res.feedsportal.com/viral/bookmark_nl.cfm?title=Barclays%3A+Sirius+XM+Radio+verkopen.&amp;link=http%3A%2F%2Fwww.analist.be%2Frss_be.php%3Fid%3D120421" target="_blank"&gt;&lt;img src="http://rss.feedsportal.com/images/bookmark.gif" border="0" /&gt;&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;br/&gt;&lt;br/&gt;&lt;a href="http://da.feedsportal.com/r/126178220253/u/0/f/8249/c/634/s/1c74b57c/a2.htm"&gt;&lt;img src="http://da.feedsportal.com/r/126178220253/u/0/f/8249/c/634/s/1c74b57c/a2.img" border="0"/&gt;&lt;/a&gt;</description><pubDate>Tue, 07 Feb 2012 09:18:57 GMT</pubDate><guid isPermaLink="false">http://www.analist.be/rss_be.php?id=120421</guid></item><item><title>Barclays: GEA Group kopen.</title><link>http://rss.feedsportal.com/c/634/f/8249/s/1c74b57b/l/0L0Sanalist0Bbe0Crss0Ibe0Bphp0Did0F120A40A3/story01.htm</link><description>Glasgow - Op 7-2-2012 herhalen de analisten van Barclays hun koopadvies voor GEA Group (ISIN: DE0006602006 / Mnemo: GEAGF / WKN: 660200).nnHet 12-maands koersdoel voor GEA Group wordt neerwaarts bijgesteld van 27.00 euro naar 26.50 euro. In 2010 bedroeg de.. (lees verder op: www.analist.be)&lt;img width='1' height='1' src='http://rss.feedsportal.com/c/634/f/8249/s/1c74b57b/mf.gif' border='0'/&gt;&lt;div class='mf-viral'&gt;&lt;table border='0'&gt;&lt;tr&gt;&lt;td valign='middle'&gt;&lt;a href="http://res.feedsportal.com/viral/sendEmail.cfm?lang=nl&amp;title=Barclays%3A+GEA+Group++kopen.&amp;link=http%3A%2F%2Fwww.analist.be%2Frss_be.php%3Fid%3D120403" target="_blank"&gt;&lt;img src="http://res3.feedsportal.com/images/emailthis2_nl.gif" border="0" /&gt;&lt;/a&gt;&lt;/td&gt;&lt;td valign='middle'&gt;&lt;a href="http://res.feedsportal.com/viral/bookmark_nl.cfm?title=Barclays%3A+GEA+Group++kopen.&amp;link=http%3A%2F%2Fwww.analist.be%2Frss_be.php%3Fid%3D120403" target="_blank"&gt;&lt;img src="http://rss.feedsportal.com/images/bookmark.gif" border="0" /&gt;&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;br/&gt;&lt;br/&gt;&lt;a href="http://da.feedsportal.com/r/126178220252/u/0/f/8249/c/634/s/1c74b57b/a2.htm"&gt;&lt;img src="http://da.feedsportal.com/r/126178220252/u/0/f/8249/c/634/s/1c74b57b/a2.img" border="0"/&gt;&lt;/a&gt;</description><pubDate>Tue, 07 Feb 2012 09:18:57 GMT</pubDate><guid isPermaLink="false">http://www.analist.be/rss_be.php?id=120403</guid></item><item><title>Berenberg: Symrise houden.</title><link>http://rss.feedsportal.com/c/634/f/8249/s/1c74b57a/l/0L0Sanalist0Bbe0Crss0Ibe0Bphp0Did0F120A416/story01.htm</link><description>Hamburg - Op 7-2-2012 verlagen de analisten van Berenberg hun advies voor Symrise (ISIN: DE000SYM9999 / Mnemo: SYIEF / WKN: SYM999) van kopen naar houden.nnEen koersdoel wordt niet afgegeven. In 2010 bedroeg de koerswinstverhouding (berekend met de ultimo slotkoers.. (lees verder op: www.analist.be)&lt;img width='1' height='1' src='http://rss.feedsportal.com/c/634/f/8249/s/1c74b57a/mf.gif' border='0'/&gt;&lt;div class='mf-viral'&gt;&lt;table border='0'&gt;&lt;tr&gt;&lt;td valign='middle'&gt;&lt;a href="http://res.feedsportal.com/viral/sendEmail.cfm?lang=nl&amp;title=Berenberg%3A+Symrise++houden.&amp;link=http%3A%2F%2Fwww.analist.be%2Frss_be.php%3Fid%3D120416" target="_blank"&gt;&lt;img src="http://res3.feedsportal.com/images/emailthis2_nl.gif" border="0" /&gt;&lt;/a&gt;&lt;/td&gt;&lt;td valign='middle'&gt;&lt;a href="http://res.feedsportal.com/viral/bookmark_nl.cfm?title=Berenberg%3A+Symrise++houden.&amp;link=http%3A%2F%2Fwww.analist.be%2Frss_be.php%3Fid%3D120416" target="_blank"&gt;&lt;img src="http://rss.feedsportal.com/images/bookmark.gif" border="0" /&gt;&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;br/&gt;&lt;br/&gt;&lt;a href="http://da.feedsportal.com/r/126178220251/u/0/f/8249/c/634/s/1c74b57a/a2.htm"&gt;&lt;img src="http://da.feedsportal.com/r/126178220251/u/0/f/8249/c/634/s/1c74b57a/a2.img" border="0"/&gt;&lt;/a&gt;</description><pubDate>Tue, 07 Feb 2012 09:18:57 GMT</pubDate><guid isPermaLink="false">http://www.analist.be/rss_be.php?id=120416</guid></item><item><title>Berenberg: IVG Immobilien kopen.</title><link>http://rss.feedsportal.com/c/634/f/8249/s/1c74b579/l/0L0Sanalist0Bbe0Crss0Ibe0Bphp0Did0F120A40A6/story01.htm</link><description>Hamburg - Op 7-2-2012 herhalen de analisten van Berenberg hun koopadvies voor IVG Immobilien (ISIN: DE0006205701 / WKN: 620570).nnHet 12-maands koersdoel voor IVG Immobilien wordt neerwaarts bijgesteld van 6.00 euro naar 3.30 euro. In 2010 bedroeg de.. (lees verder op: www.analist.be)&lt;img width='1' height='1' src='http://rss.feedsportal.com/c/634/f/8249/s/1c74b579/mf.gif' border='0'/&gt;&lt;div class='mf-viral'&gt;&lt;table border='0'&gt;&lt;tr&gt;&lt;td valign='middle'&gt;&lt;a href="http://res.feedsportal.com/viral/sendEmail.cfm?lang=nl&amp;title=Berenberg%3A+IVG+Immobilien++kopen.&amp;link=http%3A%2F%2Fwww.analist.be%2Frss_be.php%3Fid%3D120406" target="_blank"&gt;&lt;img src="http://res3.feedsportal.com/images/emailthis2_nl.gif" border="0" /&gt;&lt;/a&gt;&lt;/td&gt;&lt;td valign='middle'&gt;&lt;a href="http://res.feedsportal.com/viral/bookmark_nl.cfm?title=Berenberg%3A+IVG+Immobilien++kopen.&amp;link=http%3A%2F%2Fwww.analist.be%2Frss_be.php%3Fid%3D120406" target="_blank"&gt;&lt;img src="http://rss.feedsportal.com/images/bookmark.gif" border="0" /&gt;&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;br/&gt;&lt;br/&gt;&lt;a href="http://da.feedsportal.com/r/126178220250/u/0/f/8249/c/634/s/1c74b579/a2.htm"&gt;&lt;img src="http://da.feedsportal.com/r/126178220250/u/0/f/8249/c/634/s/1c74b579/a2.img" border="0"/&gt;&lt;/a&gt;</description><pubDate>Tue, 07 Feb 2012 09:18:57 GMT</pubDate><guid isPermaLink="false">http://www.analist.be/rss_be.php?id=120406</guid></item><item><title>Berenberg: DSM houden.</title><link>http://rss.feedsportal.com/c/634/f/8249/s/1c74b578/l/0L0Sanalist0Bbe0Crss0Ibe0Bphp0Did0F120A40A2/story01.htm</link><description>Hamburg - Op 7-2-2012 verlagen de analisten van Berenberg hun advies voor het Nederlandse chemieconcern DSM (ISIN: NL0000009827 / Mnemo: DSM) van kopen naar houden.nnEen koersdoel wordt niet afgegeven. In 2010 bedroeg de koerswinstverhouding (berekend met de ultimo.. (lees verder op: www.analist.be)&lt;img width='1' height='1' src='http://rss.feedsportal.com/c/634/f/8249/s/1c74b578/mf.gif' border='0'/&gt;&lt;div class='mf-viral'&gt;&lt;table border='0'&gt;&lt;tr&gt;&lt;td valign='middle'&gt;&lt;a href="http://res.feedsportal.com/viral/sendEmail.cfm?lang=nl&amp;title=Berenberg%3A+DSM+houden.&amp;link=http%3A%2F%2Fwww.analist.be%2Frss_be.php%3Fid%3D120402" target="_blank"&gt;&lt;img src="http://res3.feedsportal.com/images/emailthis2_nl.gif" border="0" /&gt;&lt;/a&gt;&lt;/td&gt;&lt;td valign='middle'&gt;&lt;a href="http://res.feedsportal.com/viral/bookmark_nl.cfm?title=Berenberg%3A+DSM+houden.&amp;link=http%3A%2F%2Fwww.analist.be%2Frss_be.php%3Fid%3D120402" target="_blank"&gt;&lt;img src="http://rss.feedsportal.com/images/bookmark.gif" border="0" /&gt;&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;br/&gt;&lt;br/&gt;&lt;a href="http://da.feedsportal.com/r/126178220249/u/0/f/8249/c/634/s/1c74b578/a2.htm"&gt;&lt;img src="http://da.feedsportal.com/r/126178220249/u/0/f/8249/c/634/s/1c74b578/a2.img" border="0"/&gt;&lt;/a&gt;</description><pubDate>Tue, 07 Feb 2012 09:18:57 GMT</pubDate><guid isPermaLink="false">http://www.analist.be/rss_be.php?id=120402</guid></item><item><title>Berenberg: AkzoNobel houden.</title><link>http://rss.feedsportal.com/c/634/f/8249/s/1c74b577/l/0L0Sanalist0Bbe0Crss0Ibe0Bphp0Did0F120A396/story01.htm</link><description>Hamburg - Op 7-2-2012 verhogen de analisten van Berenberg hun advies voor het Arnhemse chemieconcern AkzoNobel (ISIN: NL0000009132 / Mnemo: AKZA) van verkopen naar houden.nnEen koersdoel wordt niet afgegeven. In 2010 bedroeg de koerswinstverhouding (berekend met de.. (lees verder op: www.analist.be)&lt;img width='1' height='1' src='http://rss.feedsportal.com/c/634/f/8249/s/1c74b577/mf.gif' border='0'/&gt;&lt;div class='mf-viral'&gt;&lt;table border='0'&gt;&lt;tr&gt;&lt;td valign='middle'&gt;&lt;a href="http://res.feedsportal.com/viral/sendEmail.cfm?lang=nl&amp;title=Berenberg%3A+AkzoNobel+houden.&amp;link=http%3A%2F%2Fwww.analist.be%2Frss_be.php%3Fid%3D120396" target="_blank"&gt;&lt;img src="http://res3.feedsportal.com/images/emailthis2_nl.gif" border="0" /&gt;&lt;/a&gt;&lt;/td&gt;&lt;td valign='middle'&gt;&lt;a href="http://res.feedsportal.com/viral/bookmark_nl.cfm?title=Berenberg%3A+AkzoNobel+houden.&amp;link=http%3A%2F%2Fwww.analist.be%2Frss_be.php%3Fid%3D120396" target="_blank"&gt;&lt;img src="http://rss.feedsportal.com/images/bookmark.gif" border="0" /&gt;&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;br/&gt;&lt;br/&gt;&lt;a href="http://da.feedsportal.com/r/126178220248/u/0/f/8249/c/634/s/1c74b577/a2.htm"&gt;&lt;img src="http://da.feedsportal.com/r/126178220248/u/0/f/8249/c/634/s/1c74b577/a2.img" border="0"/&gt;&lt;/a&gt;</description><pubDate>Tue, 07 Feb 2012 09:18:56 GMT</pubDate><guid isPermaLink="false">http://www.analist.be/rss_be.php?id=120396</guid></item><item><title>Robert W. Baird: Amylin kopen.</title><link>http://rss.feedsportal.com/c/634/f/8249/s/1c74b576/l/0L0Sanalist0Bbe0Crss0Ibe0Bphp0Did0F120A420A/story01.htm</link><description>Milwaukee - Op 7-2-2012 herhalen de analisten van Robert W. Baird hun koopadvies voor de Amerikaanse pharmaceut Amylin (ISIN: US0323461089).nnHet 12-maands koersdoel voor het aandeel Amylin is vastgesteld op 19.00 USD. In 2010 bedroeg de koerswinstverhouding (berekend met.. (lees verder op: www.analist.be)&lt;img width='1' height='1' src='http://rss.feedsportal.com/c/634/f/8249/s/1c74b576/mf.gif' border='0'/&gt;&lt;div class='mf-viral'&gt;&lt;table border='0'&gt;&lt;tr&gt;&lt;td valign='middle'&gt;&lt;a href="http://res.feedsportal.com/viral/sendEmail.cfm?lang=nl&amp;title=Robert+W.+Baird%3A+Amylin+kopen.&amp;link=http%3A%2F%2Fwww.analist.be%2Frss_be.php%3Fid%3D120420" target="_blank"&gt;&lt;img src="http://res3.feedsportal.com/images/emailthis2_nl.gif" border="0" /&gt;&lt;/a&gt;&lt;/td&gt;&lt;td valign='middle'&gt;&lt;a href="http://res.feedsportal.com/viral/bookmark_nl.cfm?title=Robert+W.+Baird%3A+Amylin+kopen.&amp;link=http%3A%2F%2Fwww.analist.be%2Frss_be.php%3Fid%3D120420" target="_blank"&gt;&lt;img src="http://rss.feedsportal.com/images/bookmark.gif" border="0" /&gt;&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;br/&gt;&lt;br/&gt;&lt;a href="http://da.feedsportal.com/r/126178220247/u/0/f/8249/c/634/s/1c74b576/a2.htm"&gt;&lt;img src="http://da.feedsportal.com/r/126178220247/u/0/f/8249/c/634/s/1c74b576/a2.img" border="0"/&gt;&lt;/a&gt;</description><pubDate>Tue, 07 Feb 2012 09:18:56 GMT</pubDate><guid isPermaLink="false">http://www.analist.be/rss_be.php?id=120420</guid></item><item><title>UBS: LVMH kopen.</title><link>http://rss.feedsportal.com/c/634/f/8249/s/1c74b575/l/0L0Sanalist0Bbe0Crss0Ibe0Bphp0Did0F120A40A9/story01.htm</link><description>Londen - Op 7-2-2012 herhalen de analisten van UBS hun koopadvies voor het Franse conglomeraat LVMH (ISIN: FR0000121014).nnHet 12-maands koersdoel voor LVMH wordt opwaarts bijgesteld van 125.00 euro naar 141.00 euro. In 2010 bedroeg de koerswinstverhouding (berekend met de.. (lees verder op: www.analist.be)&lt;img width='1' height='1' src='http://rss.feedsportal.com/c/634/f/8249/s/1c74b575/mf.gif' border='0'/&gt;&lt;div class='mf-viral'&gt;&lt;table border='0'&gt;&lt;tr&gt;&lt;td valign='middle'&gt;&lt;a href="http://res.feedsportal.com/viral/sendEmail.cfm?lang=nl&amp;title=UBS%3A+LVMH+kopen.&amp;link=http%3A%2F%2Fwww.analist.be%2Frss_be.php%3Fid%3D120409" target="_blank"&gt;&lt;img src="http://res3.feedsportal.com/images/emailthis2_nl.gif" border="0" /&gt;&lt;/a&gt;&lt;/td&gt;&lt;td valign='middle'&gt;&lt;a href="http://res.feedsportal.com/viral/bookmark_nl.cfm?title=UBS%3A+LVMH+kopen.&amp;link=http%3A%2F%2Fwww.analist.be%2Frss_be.php%3Fid%3D120409" target="_blank"&gt;&lt;img src="http://rss.feedsportal.com/images/bookmark.gif" border="0" /&gt;&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;br/&gt;&lt;br/&gt;&lt;a href="http://da.feedsportal.com/r/126178220246/u/0/f/8249/c/634/s/1c74b575/a2.htm"&gt;&lt;img src="http://da.feedsportal.com/r/126178220246/u/0/f/8249/c/634/s/1c74b575/a2.img" border="0"/&gt;&lt;/a&gt;</description><pubDate>Tue, 07 Feb 2012 09:18:56 GMT</pubDate><guid isPermaLink="false">http://www.analist.be/rss_be.php?id=120409</guid></item><item><title>UBS: GEA Group kopen.</title><link>http://rss.feedsportal.com/c/634/f/8249/s/1c74b574/l/0L0Sanalist0Bbe0Crss0Ibe0Bphp0Did0F120A40A4/story01.htm</link><description>Londen - Op 7-2-2012 herhalen de analisten van UBS hun koopadvies voor GEA Group (ISIN: DE0006602006 / Mnemo: GEAGF / WKN: 660200).nnHet 12-maands koersdoel voor GEA Group wordt opwaarts bijgesteld van 29.00 euro naar 31.00 euro. In 2010 bedroeg de koerswinstverhouding.. (lees verder op: www.analist.be)&lt;img width='1' height='1' src='http://rss.feedsportal.com/c/634/f/8249/s/1c74b574/mf.gif' border='0'/&gt;&lt;div class='mf-viral'&gt;&lt;table border='0'&gt;&lt;tr&gt;&lt;td valign='middle'&gt;&lt;a href="http://res.feedsportal.com/viral/sendEmail.cfm?lang=nl&amp;title=UBS%3A+GEA+Group++kopen.&amp;link=http%3A%2F%2Fwww.analist.be%2Frss_be.php%3Fid%3D120404" target="_blank"&gt;&lt;img src="http://res3.feedsportal.com/images/emailthis2_nl.gif" border="0" /&gt;&lt;/a&gt;&lt;/td&gt;&lt;td valign='middle'&gt;&lt;a href="http://res.feedsportal.com/viral/bookmark_nl.cfm?title=UBS%3A+GEA+Group++kopen.&amp;link=http%3A%2F%2Fwww.analist.be%2Frss_be.php%3Fid%3D120404" target="_blank"&gt;&lt;img src="http://rss.feedsportal.com/images/bookmark.gif" border="0" /&gt;&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;br/&gt;&lt;br/&gt;&lt;a href="http://da.feedsportal.com/r/126178220245/u/0/f/8249/c/634/s/1c74b574/a2.htm"&gt;&lt;img src="http://da.feedsportal.com/r/126178220245/u/0/f/8249/c/634/s/1c74b574/a2.img" border="0"/&gt;&lt;/a&gt;</description><pubDate>Tue, 07 Feb 2012 09:18:56 GMT</pubDate><guid isPermaLink="false">http://www.analist.be/rss_be.php?id=120404</guid></item><item><title>UBS: Deutsche Börse kopen.</title><link>http://rss.feedsportal.com/c/634/f/8249/s/1c74b573/l/0L0Sanalist0Bbe0Crss0Ibe0Bphp0Did0F120A40A1/story01.htm</link><description>Londen - Op 7-2-2012 herhalen de analisten van UBS hun koopadvies voor het Duitse beursbedrijf Deutsche Börse (ISIN: DE0005810055).nnHet 12-maands koersdoel voor Deutsche Börse wordt opwaarts bijgesteld van 56.00 euro naar 58.00 euro. In 2010 bedroeg de.. (lees verder op: www.analist.be)&lt;img width='1' height='1' src='http://rss.feedsportal.com/c/634/f/8249/s/1c74b573/mf.gif' border='0'/&gt;&lt;div class='mf-viral'&gt;&lt;table border='0'&gt;&lt;tr&gt;&lt;td valign='middle'&gt;&lt;a href="http://res.feedsportal.com/viral/sendEmail.cfm?lang=nl&amp;title=UBS%3A+Deutsche+B%C3%B6rse+kopen.&amp;link=http%3A%2F%2Fwww.analist.be%2Frss_be.php%3Fid%3D120401" target="_blank"&gt;&lt;img src="http://res3.feedsportal.com/images/emailthis2_nl.gif" border="0" /&gt;&lt;/a&gt;&lt;/td&gt;&lt;td valign='middle'&gt;&lt;a href="http://res.feedsportal.com/viral/bookmark_nl.cfm?title=UBS%3A+Deutsche+B%C3%B6rse+kopen.&amp;link=http%3A%2F%2Fwww.analist.be%2Frss_be.php%3Fid%3D120401" target="_blank"&gt;&lt;img src="http://rss.feedsportal.com/images/bookmark.gif" border="0" /&gt;&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;br/&gt;&lt;br/&gt;&lt;a href="http://da.feedsportal.com/r/126178220244/u/0/f/8249/c/634/s/1c74b573/a2.htm"&gt;&lt;img src="http://da.feedsportal.com/r/126178220244/u/0/f/8249/c/634/s/1c74b573/a2.img" border="0"/&gt;&lt;/a&gt;</description><pubDate>Tue, 07 Feb 2012 09:18:56 GMT</pubDate><guid isPermaLink="false">http://www.analist.be/rss_be.php?id=120401</guid></item><item><title>UBS: Cairn Energy kopen.</title><link>http://rss.feedsportal.com/c/634/f/8249/s/1c74b572/l/0L0Sanalist0Bbe0Crss0Ibe0Bphp0Did0F120A398/story01.htm</link><description>Londen - Op 7-2-2012 herhalen de analisten van UBS hun koopadvies voor het Britse energiebedrijf Cairn Energy (ISIN: GB0032399312).nnHet 12-maands koersdoel voor Cairn Energy wordt opwaarts bijgesteld van 355.00 GBp naar 370.00 GBp. In 2010 bedroeg de koerswinstverhouding.. (lees verder op: www.analist.be)&lt;img width='1' height='1' src='http://rss.feedsportal.com/c/634/f/8249/s/1c74b572/mf.gif' border='0'/&gt;&lt;div class='mf-viral'&gt;&lt;table border='0'&gt;&lt;tr&gt;&lt;td valign='middle'&gt;&lt;a href="http://res.feedsportal.com/viral/sendEmail.cfm?lang=nl&amp;title=UBS%3A+Cairn+Energy+kopen.&amp;link=http%3A%2F%2Fwww.analist.be%2Frss_be.php%3Fid%3D120398" target="_blank"&gt;&lt;img src="http://res3.feedsportal.com/images/emailthis2_nl.gif" border="0" /&gt;&lt;/a&gt;&lt;/td&gt;&lt;td valign='middle'&gt;&lt;a href="http://res.feedsportal.com/viral/bookmark_nl.cfm?title=UBS%3A+Cairn+Energy+kopen.&amp;link=http%3A%2F%2Fwww.analist.be%2Frss_be.php%3Fid%3D120398" target="_blank"&gt;&lt;img src="http://rss.feedsportal.com/images/bookmark.gif" border="0" /&gt;&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;br/&gt;&lt;br/&gt;&lt;a href="http://da.feedsportal.com/r/126178220243/u/0/f/8249/c/634/s/1c74b572/a2.htm"&gt;&lt;img src="http://da.feedsportal.com/r/126178220243/u/0/f/8249/c/634/s/1c74b572/a2.img" border="0"/&gt;&lt;/a&gt;</description><pubDate>Tue, 07 Feb 2012 09:18:56 GMT</pubDate><guid isPermaLink="false">http://www.analist.be/rss_be.php?id=120398</guid></item><item><title>SNS Securities: Brill kopen.</title><link>http://rss.feedsportal.com/c/634/f/8249/s/1c74b571/l/0L0Sanalist0Bbe0Crss0Ibe0Bphp0Did0F120A422/story01.htm</link><description>Amsterdam - Op 7-2-2012 herhalen de analisten van SNS Securities hun koopadvies voor Brill (ISIN: NL0000442523).nnHet 12-maands koersdoel voor Brill blijft gehandhaafd op 16.00 euro. In 2010 bedroeg de koerswinstverhouding (berekend met de ultimo slotkoers van het aandeel.. (lees verder op: www.analist.be)&lt;img width='1' height='1' src='http://rss.feedsportal.com/c/634/f/8249/s/1c74b571/mf.gif' border='0'/&gt;&lt;div class='mf-viral'&gt;&lt;table border='0'&gt;&lt;tr&gt;&lt;td valign='middle'&gt;&lt;a href="http://res.feedsportal.com/viral/sendEmail.cfm?lang=nl&amp;title=SNS+Securities%3A+Brill+kopen.&amp;link=http%3A%2F%2Fwww.analist.be%2Frss_be.php%3Fid%3D120422" target="_blank"&gt;&lt;img src="http://res3.feedsportal.com/images/emailthis2_nl.gif" border="0" /&gt;&lt;/a&gt;&lt;/td&gt;&lt;td valign='middle'&gt;&lt;a href="http://res.feedsportal.com/viral/bookmark_nl.cfm?title=SNS+Securities%3A+Brill+kopen.&amp;link=http%3A%2F%2Fwww.analist.be%2Frss_be.php%3Fid%3D120422" target="_blank"&gt;&lt;img src="http://rss.feedsportal.com/images/bookmark.gif" border="0" /&gt;&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;br/&gt;&lt;br/&gt;&lt;a href="http://da.feedsportal.com/r/126178220242/u/0/f/8249/c/634/s/1c74b571/a2.htm"&gt;&lt;img src="http://da.feedsportal.com/r/126178220242/u/0/f/8249/c/634/s/1c74b571/a2.img" border="0"/&gt;&lt;/a&gt;</description><pubDate>Tue, 07 Feb 2012 09:18:56 GMT</pubDate><guid isPermaLink="false">http://www.analist.be/rss_be.php?id=120422</guid></item><item><title>Citigroup: Amylin houden.</title><link>http://rss.feedsportal.com/c/634/f/8249/s/1c74b570/l/0L0Sanalist0Bbe0Crss0Ibe0Bphp0Did0F120A419/story01.htm</link><description>New York - Op 7-2-2012 herhalen de analisten van Citigroup hun houdadvies voor de Amerikaanse pharmaceut Amylin (ISIN: US0323461089).nnHet 12-maands koersdoel voor Amylin wordt opwaarts bijgesteld van 12.00 USD naar 18.00 USD. In 2010 bedroeg de koerswinstverhouding.. (lees verder op: www.analist.be)&lt;img width='1' height='1' src='http://rss.feedsportal.com/c/634/f/8249/s/1c74b570/mf.gif' border='0'/&gt;&lt;div class='mf-viral'&gt;&lt;table border='0'&gt;&lt;tr&gt;&lt;td valign='middle'&gt;&lt;a href="http://res.feedsportal.com/viral/sendEmail.cfm?lang=nl&amp;title=Citigroup%3A+Amylin+houden.&amp;link=http%3A%2F%2Fwww.analist.be%2Frss_be.php%3Fid%3D120419" target="_blank"&gt;&lt;img src="http://res3.feedsportal.com/images/emailthis2_nl.gif" border="0" /&gt;&lt;/a&gt;&lt;/td&gt;&lt;td valign='middle'&gt;&lt;a href="http://res.feedsportal.com/viral/bookmark_nl.cfm?title=Citigroup%3A+Amylin+houden.&amp;link=http%3A%2F%2Fwww.analist.be%2Frss_be.php%3Fid%3D120419" target="_blank"&gt;&lt;img src="http://rss.feedsportal.com/images/bookmark.gif" border="0" /&gt;&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;br/&gt;&lt;br/&gt;&lt;a href="http://da.feedsportal.com/r/126178220241/u/0/f/8249/c/634/s/1c74b570/a2.htm"&gt;&lt;img src="http://da.feedsportal.com/r/126178220241/u/0/f/8249/c/634/s/1c74b570/a2.img" border="0"/&gt;&lt;/a&gt;</description><pubDate>Tue, 07 Feb 2012 09:18:56 GMT</pubDate><guid isPermaLink="false">http://www.analist.be/rss_be.php?id=120419</guid></item><item><title>Citigroup: Rolls-Royce kopen.</title><link>http://rss.feedsportal.com/c/634/f/8249/s/1c74b56f/l/0L0Sanalist0Bbe0Crss0Ibe0Bphp0Did0F120A413/story01.htm</link><description>New York - Op 7-2-2012 herhalen de analisten van Citigroup hun koopadvies voor het Britse conglomeraat Rolls-Royce (ISIN: GB0032836487).nnHet 12-maands koersdoel voor Rolls-Royce wordt opwaarts bijgesteld van 820.00 GBp naar 840.00 GBp. In 2010 bedroeg de.. (lees verder op: www.analist.be)&lt;img width='1' height='1' src='http://rss.feedsportal.com/c/634/f/8249/s/1c74b56f/mf.gif' border='0'/&gt;&lt;div class='mf-viral'&gt;&lt;table border='0'&gt;&lt;tr&gt;&lt;td valign='middle'&gt;&lt;a href="http://res.feedsportal.com/viral/sendEmail.cfm?lang=nl&amp;title=Citigroup%3A+Rolls-Royce+kopen.&amp;link=http%3A%2F%2Fwww.analist.be%2Frss_be.php%3Fid%3D120413" target="_blank"&gt;&lt;img src="http://res3.feedsportal.com/images/emailthis2_nl.gif" border="0" /&gt;&lt;/a&gt;&lt;/td&gt;&lt;td valign='middle'&gt;&lt;a href="http://res.feedsportal.com/viral/bookmark_nl.cfm?title=Citigroup%3A+Rolls-Royce+kopen.&amp;link=http%3A%2F%2Fwww.analist.be%2Frss_be.php%3Fid%3D120413" target="_blank"&gt;&lt;img src="http://rss.feedsportal.com/images/bookmark.gif" border="0" /&gt;&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;br/&gt;&lt;br/&gt;&lt;a href="http://da.feedsportal.com/r/126178220240/u/0/f/8249/c/634/s/1c74b56f/a2.htm"&gt;&lt;img src="http://da.feedsportal.com/r/126178220240/u/0/f/8249/c/634/s/1c74b56f/a2.img" border="0"/&gt;&lt;/a&gt;</description><pubDate>Tue, 07 Feb 2012 09:18:55 GMT</pubDate><guid isPermaLink="false">http://www.analist.be/rss_be.php?id=120413</guid></item><item><title>Citigroup: Liberty Global houden.</title><link>http://rss.feedsportal.com/c/634/f/8249/s/1c74b56e/l/0L0Sanalist0Bbe0Crss0Ibe0Bphp0Did0F120A40A8/story01.htm</link><description>New York - Op 7-2-2012 herhalen de analisten van Citigroup hun houdadvies voor het Amerikaanse kabelbedrijf Liberty Global (ISIN: US5307191032).nnHet 12-maands koersdoel voor het aandeel Liberty Global is vastgesteld op 50.00 USD. In 2010 bedroeg de koerswinstverhouding.. (lees verder op: www.analist.be)&lt;img width='1' height='1' src='http://rss.feedsportal.com/c/634/f/8249/s/1c74b56e/mf.gif' border='0'/&gt;&lt;div class='mf-viral'&gt;&lt;table border='0'&gt;&lt;tr&gt;&lt;td valign='middle'&gt;&lt;a href="http://res.feedsportal.com/viral/sendEmail.cfm?lang=nl&amp;title=Citigroup%3A+Liberty+Global+houden.&amp;link=http%3A%2F%2Fwww.analist.be%2Frss_be.php%3Fid%3D120408" target="_blank"&gt;&lt;img src="http://res3.feedsportal.com/images/emailthis2_nl.gif" border="0" /&gt;&lt;/a&gt;&lt;/td&gt;&lt;td valign='middle'&gt;&lt;a href="http://res.feedsportal.com/viral/bookmark_nl.cfm?title=Citigroup%3A+Liberty+Global+houden.&amp;link=http%3A%2F%2Fwww.analist.be%2Frss_be.php%3Fid%3D120408" target="_blank"&gt;&lt;img src="http://rss.feedsportal.com/images/bookmark.gif" border="0" /&gt;&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;br/&gt;&lt;br/&gt;&lt;a href="http://da.feedsportal.com/r/126178220239/u/0/f/8249/c/634/s/1c74b56e/a2.htm"&gt;&lt;img src="http://da.feedsportal.com/r/126178220239/u/0/f/8249/c/634/s/1c74b56e/a2.img" border="0"/&gt;&lt;/a&gt;</description><pubDate>Tue, 07 Feb 2012 09:18:55 GMT</pubDate><guid isPermaLink="false">http://www.analist.be/rss_be.php?id=120408</guid></item><item><title>Citigroup: KPN houden.</title><link>http://rss.feedsportal.com/c/634/f/8249/s/1c74b56d/l/0L0Sanalist0Bbe0Crss0Ibe0Bphp0Did0F120A40A7/story01.htm</link><description>New York - Op 7-2-2012 (her)starten de analisten van Citigroup met het volgen van het Nederlandse telecommunicatiebedrijf KPN (ISIN: NL0000009082 / Mnemo: KPN) met een houdadvies. nnHet 12-maands koersdoel voor KPN wordt neerwaarts bijgesteld van 12.00 euro naar 7.50 euro... (lees verder op: www.analist.be)&lt;img width='1' height='1' src='http://rss.feedsportal.com/c/634/f/8249/s/1c74b56d/mf.gif' border='0'/&gt;&lt;div class='mf-viral'&gt;&lt;table border='0'&gt;&lt;tr&gt;&lt;td valign='middle'&gt;&lt;a href="http://res.feedsportal.com/viral/sendEmail.cfm?lang=nl&amp;title=Citigroup%3A+KPN+houden.&amp;link=http%3A%2F%2Fwww.analist.be%2Frss_be.php%3Fid%3D120407" target="_blank"&gt;&lt;img src="http://res3.feedsportal.com/images/emailthis2_nl.gif" border="0" /&gt;&lt;/a&gt;&lt;/td&gt;&lt;td valign='middle'&gt;&lt;a href="http://res.feedsportal.com/viral/bookmark_nl.cfm?title=Citigroup%3A+KPN+houden.&amp;link=http%3A%2F%2Fwww.analist.be%2Frss_be.php%3Fid%3D120407" target="_blank"&gt;&lt;img src="http://rss.feedsportal.com/images/bookmark.gif" border="0" /&gt;&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;br/&gt;&lt;br/&gt;&lt;a href="http://da.feedsportal.com/r/126178220238/u/0/f/8249/c/634/s/1c74b56d/a2.htm"&gt;&lt;img src="http://da.feedsportal.com/r/126178220238/u/0/f/8249/c/634/s/1c74b56d/a2.img" border="0"/&gt;&lt;/a&gt;</description><pubDate>Tue, 07 Feb 2012 09:18:55 GMT</pubDate><guid isPermaLink="false">http://www.analist.be/rss_be.php?id=120407</guid></item><item><title>Citigroup: Continental kopen.</title><link>http://rss.feedsportal.com/c/634/f/8249/s/1c74b56c/l/0L0Sanalist0Bbe0Crss0Ibe0Bphp0Did0F120A399/story01.htm</link><description>New York - Op 7-2-2012 herhalen de analisten van Citigroup hun koopadvies voor de Duitse bandenproducent Continental (ISIN: DE0005439004).nnHet 12-maands koersdoel voor Continental wordt opwaarts bijgesteld van 69.00 euro naar 80.00 euro. In 2010 bedroeg de.. (lees verder op: www.analist.be)&lt;img width='1' height='1' src='http://rss.feedsportal.com/c/634/f/8249/s/1c74b56c/mf.gif' border='0'/&gt;&lt;div class='mf-viral'&gt;&lt;table border='0'&gt;&lt;tr&gt;&lt;td valign='middle'&gt;&lt;a href="http://res.feedsportal.com/viral/sendEmail.cfm?lang=nl&amp;title=Citigroup%3A+Continental+kopen.&amp;link=http%3A%2F%2Fwww.analist.be%2Frss_be.php%3Fid%3D120399" target="_blank"&gt;&lt;img src="http://res3.feedsportal.com/images/emailthis2_nl.gif" border="0" /&gt;&lt;/a&gt;&lt;/td&gt;&lt;td valign='middle'&gt;&lt;a href="http://res.feedsportal.com/viral/bookmark_nl.cfm?title=Citigroup%3A+Continental+kopen.&amp;link=http%3A%2F%2Fwww.analist.be%2Frss_be.php%3Fid%3D120399" target="_blank"&gt;&lt;img src="http://rss.feedsportal.com/images/bookmark.gif" border="0" /&gt;&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;br/&gt;&lt;br/&gt;&lt;a href="http://da.feedsportal.com/r/126178220237/u/0/f/8249/c/634/s/1c74b56c/a2.htm"&gt;&lt;img src="http://da.feedsportal.com/r/126178220237/u/0/f/8249/c/634/s/1c74b56c/a2.img" border="0"/&gt;&lt;/a&gt;</description><pubDate>Tue, 07 Feb 2012 09:18:55 GMT</pubDate><guid isPermaLink="false">http://www.analist.be/rss_be.php?id=120399</guid></item><item><title>Citigroup: Alcatel-Lucent verkopen.</title><link>http://rss.feedsportal.com/c/634/f/8249/s/1c74b56b/l/0L0Sanalist0Bbe0Crss0Ibe0Bphp0Did0F120A395/story01.htm</link><description>New York - Op 7-2-2012 herhalen de analisten van Citigroup hun verkoopadvies voor het Franse telecommunicatiebedrijf Alcatel-Lucent (ISIN: FR0000130007).nnHet 12-maands koersdoel voor Alcatel-Lucent wordt neerwaarts bijgesteld van 1.00 euro naar 0.90 euro. In 2010 bedroeg.. (lees verder op: www.analist.be)&lt;img width='1' height='1' src='http://rss.feedsportal.com/c/634/f/8249/s/1c74b56b/mf.gif' border='0'/&gt;&lt;div class='mf-viral'&gt;&lt;table border='0'&gt;&lt;tr&gt;&lt;td valign='middle'&gt;&lt;a href="http://res.feedsportal.com/viral/sendEmail.cfm?lang=nl&amp;title=Citigroup%3A+Alcatel-Lucent+verkopen.&amp;link=http%3A%2F%2Fwww.analist.be%2Frss_be.php%3Fid%3D120395" target="_blank"&gt;&lt;img src="http://res3.feedsportal.com/images/emailthis2_nl.gif" border="0" /&gt;&lt;/a&gt;&lt;/td&gt;&lt;td valign='middle'&gt;&lt;a href="http://res.feedsportal.com/viral/bookmark_nl.cfm?title=Citigroup%3A+Alcatel-Lucent+verkopen.&amp;link=http%3A%2F%2Fwww.analist.be%2Frss_be.php%3Fid%3D120395" target="_blank"&gt;&lt;img src="http://rss.feedsportal.com/images/bookmark.gif" border="0" /&gt;&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;br/&gt;&lt;br/&gt;&lt;a href="http://da.feedsportal.com/r/126178220236/u/0/f/8249/c/634/s/1c74b56b/a2.htm"&gt;&lt;img src="http://da.feedsportal.com/r/126178220236/u/0/f/8249/c/634/s/1c74b56b/a2.img" border="0"/&gt;&lt;/a&gt;</description><pubDate>Tue, 07 Feb 2012 09:18:55 GMT</pubDate><guid isPermaLink="false">http://www.analist.be/rss_be.php?id=120395</guid></item><item><title>Morgan Stanley: Teva Pharm. houden.</title><link>http://rss.feedsportal.com/c/634/f/8249/s/1c74b56a/l/0L0Sanalist0Bbe0Crss0Ibe0Bphp0Did0F120A423/story01.htm</link><description>New York - Op 7-2-2012 verlagen de analisten van Morgan Stanley hun advies voor de Amerikaanse pharmaceut Teva Pharm. (ISIN: US8816242098) van kopen naar houden.nnHet 12-maands koersdoel voor Teva Pharm. blijft gehandhaafd op 47.00 USD. In 2010 bedroeg de.. (lees verder op: www.analist.be)&lt;img width='1' height='1' src='http://rss.feedsportal.com/c/634/f/8249/s/1c74b56a/mf.gif' border='0'/&gt;&lt;div class='mf-viral'&gt;&lt;table border='0'&gt;&lt;tr&gt;&lt;td valign='middle'&gt;&lt;a href="http://res.feedsportal.com/viral/sendEmail.cfm?lang=nl&amp;title=Morgan+Stanley%3A+Teva+Pharm.+houden.&amp;link=http%3A%2F%2Fwww.analist.be%2Frss_be.php%3Fid%3D120423" target="_blank"&gt;&lt;img src="http://res3.feedsportal.com/images/emailthis2_nl.gif" border="0" /&gt;&lt;/a&gt;&lt;/td&gt;&lt;td valign='middle'&gt;&lt;a href="http://res.feedsportal.com/viral/bookmark_nl.cfm?title=Morgan+Stanley%3A+Teva+Pharm.+houden.&amp;link=http%3A%2F%2Fwww.analist.be%2Frss_be.php%3Fid%3D120423" target="_blank"&gt;&lt;img src="http://rss.feedsportal.com/images/bookmark.gif" border="0" /&gt;&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;br/&gt;&lt;br/&gt;&lt;a href="http://da.feedsportal.com/r/126178220235/u/0/f/8249/c/634/s/1c74b56a/a2.htm"&gt;&lt;img src="http://da.feedsportal.com/r/126178220235/u/0/f/8249/c/634/s/1c74b56a/a2.img" border="0"/&gt;&lt;/a&gt;</description><pubDate>Tue, 07 Feb 2012 09:18:55 GMT</pubDate><guid isPermaLink="false">http://www.analist.be/rss_be.php?id=120423</guid></item><item><title>JP Morgan: Solvay kopen.</title><link>http://rss.feedsportal.com/c/634/f/8249/s/1c74b569/l/0L0Sanalist0Bbe0Crss0Ibe0Bphp0Did0F120A415/story01.htm</link><description>New York - Op 7-2-2012 herhalen de analisten van JP Morgan hun koopadvies voor het Belgische farmaceutisch concern Solvay (ISIN: BE0003470755).nnHet 12-maands koersdoel voor Solvay wordt neerwaarts bijgesteld van 96.00 euro naar 94.00 euro. In 2010 bedroeg de.. (lees verder op: www.analist.be)&lt;img width='1' height='1' src='http://rss.feedsportal.com/c/634/f/8249/s/1c74b569/mf.gif' border='0'/&gt;&lt;div class='mf-viral'&gt;&lt;table border='0'&gt;&lt;tr&gt;&lt;td valign='middle'&gt;&lt;a href="http://res.feedsportal.com/viral/sendEmail.cfm?lang=nl&amp;title=JP+Morgan%3A+Solvay+kopen.&amp;link=http%3A%2F%2Fwww.analist.be%2Frss_be.php%3Fid%3D120415" target="_blank"&gt;&lt;img src="http://res3.feedsportal.com/images/emailthis2_nl.gif" border="0" /&gt;&lt;/a&gt;&lt;/td&gt;&lt;td valign='middle'&gt;&lt;a href="http://res.feedsportal.com/viral/bookmark_nl.cfm?title=JP+Morgan%3A+Solvay+kopen.&amp;link=http%3A%2F%2Fwww.analist.be%2Frss_be.php%3Fid%3D120415" target="_blank"&gt;&lt;img src="http://rss.feedsportal.com/images/bookmark.gif" border="0" /&gt;&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;br/&gt;&lt;br/&gt;&lt;a href="http://da.feedsportal.com/r/126178220234/u/0/f/8249/c/634/s/1c74b569/a2.htm"&gt;&lt;img src="http://da.feedsportal.com/r/126178220234/u/0/f/8249/c/634/s/1c74b569/a2.img" border="0"/&gt;&lt;/a&gt;</description><pubDate>Tue, 07 Feb 2012 09:18:54 GMT</pubDate><guid isPermaLink="false">http://www.analist.be/rss_be.php?id=120415</guid></item><item><title>Goldman Sachs: UCB houden.</title><link>http://rss.feedsportal.com/c/634/f/8249/s/1c74b568/l/0L0Sanalist0Bbe0Crss0Ibe0Bphp0Did0F120A417/story01.htm</link><description>New York - Op 7-2-2012 verhogen de analisten van Goldman Sachs hun advies voor het Belgische farmaceutisch concern UCB (ISIN: BE0003739530) van verkopen naar houden.nnEen koersdoel wordt niet afgegeven. In 2010 bedroeg de koerswinstverhouding (berekend met de ultimo.. (lees verder op: www.analist.be)&lt;img width='1' height='1' src='http://rss.feedsportal.com/c/634/f/8249/s/1c74b568/mf.gif' border='0'/&gt;&lt;div class='mf-viral'&gt;&lt;table border='0'&gt;&lt;tr&gt;&lt;td valign='middle'&gt;&lt;a href="http://res.feedsportal.com/viral/sendEmail.cfm?lang=nl&amp;title=Goldman+Sachs%3A+UCB+houden.&amp;link=http%3A%2F%2Fwww.analist.be%2Frss_be.php%3Fid%3D120417" target="_blank"&gt;&lt;img src="http://res3.feedsportal.com/images/emailthis2_nl.gif" border="0" /&gt;&lt;/a&gt;&lt;/td&gt;&lt;td valign='middle'&gt;&lt;a href="http://res.feedsportal.com/viral/bookmark_nl.cfm?title=Goldman+Sachs%3A+UCB+houden.&amp;link=http%3A%2F%2Fwww.analist.be%2Frss_be.php%3Fid%3D120417" target="_blank"&gt;&lt;img src="http://rss.feedsportal.com/images/bookmark.gif" border="0" /&gt;&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;br/&gt;&lt;br/&gt;&lt;a href="http://da.feedsportal.com/r/126178220233/u/0/f/8249/c/634/s/1c74b568/a2.htm"&gt;&lt;img src="http://da.feedsportal.com/r/126178220233/u/0/f/8249/c/634/s/1c74b568/a2.img" border="0"/&gt;&lt;/a&gt;</description><pubDate>Tue, 07 Feb 2012 09:18:54 GMT</pubDate><guid isPermaLink="false">http://www.analist.be/rss_be.php?id=120417</guid></item><item><title>Goldman Sachs: Shire kopen.</title><link>http://rss.feedsportal.com/c/634/f/8249/s/1c74b567/l/0L0Sanalist0Bbe0Crss0Ibe0Bphp0Did0F120A414/story01.htm</link><description>New York - Op 7-2-2012 herhalen de analisten van Goldman Sachs hun koopadvies voor het Britse farmaceutisch concern Shire (ISIN: US82481R1068).nnHet 12-maands koersdoel voor Shire wordt opwaarts bijgesteld van 2500.00 GBp naar 2600.00 GBp. In 2010 bedroeg de.. (lees verder op: www.analist.be)&lt;img width='1' height='1' src='http://rss.feedsportal.com/c/634/f/8249/s/1c74b567/mf.gif' border='0'/&gt;&lt;div class='mf-viral'&gt;&lt;table border='0'&gt;&lt;tr&gt;&lt;td valign='middle'&gt;&lt;a href="http://res.feedsportal.com/viral/sendEmail.cfm?lang=nl&amp;title=Goldman+Sachs%3A+Shire+kopen.&amp;link=http%3A%2F%2Fwww.analist.be%2Frss_be.php%3Fid%3D120414" target="_blank"&gt;&lt;img src="http://res3.feedsportal.com/images/emailthis2_nl.gif" border="0" /&gt;&lt;/a&gt;&lt;/td&gt;&lt;td valign='middle'&gt;&lt;a href="http://res.feedsportal.com/viral/bookmark_nl.cfm?title=Goldman+Sachs%3A+Shire+kopen.&amp;link=http%3A%2F%2Fwww.analist.be%2Frss_be.php%3Fid%3D120414" target="_blank"&gt;&lt;img src="http://rss.feedsportal.com/images/bookmark.gif" border="0" /&gt;&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;br/&gt;&lt;br/&gt;&lt;a href="http://da.feedsportal.com/r/126178220232/u/0/f/8249/c/634/s/1c74b567/a2.htm"&gt;&lt;img src="http://da.feedsportal.com/r/126178220232/u/0/f/8249/c/634/s/1c74b567/a2.img" border="0"/&gt;&lt;/a&gt;</description><pubDate>Tue, 07 Feb 2012 09:18:54 GMT</pubDate><guid isPermaLink="false">http://www.analist.be/rss_be.php?id=120414</guid></item><item><title>Goldman Sachs: Roche kopen.</title><link>http://rss.feedsportal.com/c/634/f/8249/s/1c74b566/l/0L0Sanalist0Bbe0Crss0Ibe0Bphp0Did0F120A412/story01.htm</link><description>New York - Op 7-2-2012 herhalen de analisten van Goldman Sachs hun koopadvies voor het Zwitserse farmacieconcern Roche (ISIN: CH0012032048).nnHet 12-maands koersdoel voor Roche wordt opwaarts bijgesteld van 180.00 CHF naar 200.00 CHF. In 2010 bedroeg de.. (lees verder op: www.analist.be)&lt;img width='1' height='1' src='http://rss.feedsportal.com/c/634/f/8249/s/1c74b566/mf.gif' border='0'/&gt;&lt;div class='mf-viral'&gt;&lt;table border='0'&gt;&lt;tr&gt;&lt;td valign='middle'&gt;&lt;a href="http://res.feedsportal.com/viral/sendEmail.cfm?lang=nl&amp;title=Goldman+Sachs%3A+Roche+kopen.&amp;link=http%3A%2F%2Fwww.analist.be%2Frss_be.php%3Fid%3D120412" target="_blank"&gt;&lt;img src="http://res3.feedsportal.com/images/emailthis2_nl.gif" border="0" /&gt;&lt;/a&gt;&lt;/td&gt;&lt;td valign='middle'&gt;&lt;a href="http://res.feedsportal.com/viral/bookmark_nl.cfm?title=Goldman+Sachs%3A+Roche+kopen.&amp;link=http%3A%2F%2Fwww.analist.be%2Frss_be.php%3Fid%3D120412" target="_blank"&gt;&lt;img src="http://rss.feedsportal.com/images/bookmark.gif" border="0" /&gt;&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;br/&gt;&lt;br/&gt;&lt;a href="http://da.feedsportal.com/r/126178220231/u/0/f/8249/c/634/s/1c74b566/a2.htm"&gt;&lt;img src="http://da.feedsportal.com/r/126178220231/u/0/f/8249/c/634/s/1c74b566/a2.img" border="0"/&gt;&lt;/a&gt;</description><pubDate>Tue, 07 Feb 2012 09:18:54 GMT</pubDate><guid isPermaLink="false">http://www.analist.be/rss_be.php?id=120412</guid></item><item><title>Goldman Sachs: GlaxoSmithKline houden.</title><link>http://rss.feedsportal.com/c/634/f/8249/s/1c74b565/l/0L0Sanalist0Bbe0Crss0Ibe0Bphp0Did0F120A40A5/story01.htm</link><description>New York - Op 7-2-2012 herhalen de analisten van Goldman Sachs hun houdadvies voor het Britse farmaceutisch concern GlaxoSmithKline (ISIN: US37733W1053).nnHet 12-maands koersdoel voor GlaxoSmithKline wordt opwaarts bijgesteld van 1330.00 GBp naar 1425.00 GBp. In 2010.. (lees verder op: www.analist.be)&lt;img width='1' height='1' src='http://rss.feedsportal.com/c/634/f/8249/s/1c74b565/mf.gif' border='0'/&gt;&lt;div class='mf-viral'&gt;&lt;table border='0'&gt;&lt;tr&gt;&lt;td valign='middle'&gt;&lt;a href="http://res.feedsportal.com/viral/sendEmail.cfm?lang=nl&amp;title=Goldman+Sachs%3A+GlaxoSmithKline+houden.&amp;link=http%3A%2F%2Fwww.analist.be%2Frss_be.php%3Fid%3D120405" target="_blank"&gt;&lt;img src="http://res3.feedsportal.com/images/emailthis2_nl.gif" border="0" /&gt;&lt;/a&gt;&lt;/td&gt;&lt;td valign='middle'&gt;&lt;a href="http://res.feedsportal.com/viral/bookmark_nl.cfm?title=Goldman+Sachs%3A+GlaxoSmithKline+houden.&amp;link=http%3A%2F%2Fwww.analist.be%2Frss_be.php%3Fid%3D120405" target="_blank"&gt;&lt;img src="http://rss.feedsportal.com/images/bookmark.gif" border="0" /&gt;&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;br/&gt;&lt;br/&gt;&lt;a href="http://da.feedsportal.com/r/126178220230/u/0/f/8249/c/634/s/1c74b565/a2.htm"&gt;&lt;img src="http://da.feedsportal.com/r/126178220230/u/0/f/8249/c/634/s/1c74b565/a2.img" border="0"/&gt;&lt;/a&gt;</description><pubDate>Tue, 07 Feb 2012 09:18:53 GMT</pubDate><guid isPermaLink="false">http://www.analist.be/rss_be.php?id=120405</guid></item><item><title>Credit Suisse: Suez Environnement houden.</title><link>http://rss.feedsportal.com/c/634/f/8249/s/1c74b564/l/0L0Sanalist0Bbe0Crss0Ibe0Bphp0Did0F120A426/story01.htm</link><description>Zurich - Op 7-2-2012 (her)starten de analisten van Credit Suisse met het volgen van het Belgisch/Franse energiebedrijf Suez Environnement (ISIN: NSCBE00SEVB0 ) met een houdadvies. nnHet 12-maands koersdoel voor het aandeel Suez Environnement is vastgesteld op 12.00 EUR. In.. (lees verder op: www.analist.be)&lt;img width='1' height='1' src='http://rss.feedsportal.com/c/634/f/8249/s/1c74b564/mf.gif' border='0'/&gt;&lt;div class='mf-viral'&gt;&lt;table border='0'&gt;&lt;tr&gt;&lt;td valign='middle'&gt;&lt;a href="http://res.feedsportal.com/viral/sendEmail.cfm?lang=nl&amp;title=Credit+Suisse%3A+Suez+Environnement+houden.&amp;link=http%3A%2F%2Fwww.analist.be%2Frss_be.php%3Fid%3D120426" target="_blank"&gt;&lt;img src="http://res3.feedsportal.com/images/emailthis2_nl.gif" border="0" /&gt;&lt;/a&gt;&lt;/td&gt;&lt;td valign='middle'&gt;&lt;a href="http://res.feedsportal.com/viral/bookmark_nl.cfm?title=Credit+Suisse%3A+Suez+Environnement+houden.&amp;link=http%3A%2F%2Fwww.analist.be%2Frss_be.php%3Fid%3D120426" target="_blank"&gt;&lt;img src="http://rss.feedsportal.com/images/bookmark.gif" border="0" /&gt;&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</description><pubDate>Tue, 07 Feb 2012 09:18:53 GMT</pubDate><guid isPermaLink="false">http://www.analist.be/rss_be.php?id=120426</guid></item></channel></rss>

